C型慢性肝炎に対する PEG-IFNα2b + ribavirin 併用療法における早期治療効果予測 : 血中HCV抗原によるモニタリング解析

概要

論文の詳細を見る
The capability of an early prognosis for the treatment of Chronic Hepatitis C (CH-C) patients with genotype 1b and high viral loads with Pegylated Interferon-α2b plus Ribavirin was evaluated by the levels of serum HCV core antigens. Serum samples were drawn before the treatment, 3 days or 1, 2, 4, and 12 weeks after the treatment. Out of 45 cases with CH-C, 36 cases (80%) and 9 cases (20%) were early virological response (EVR) and non-early virological response (NEVR), respectvery. The serum levels of core antigen in EVR were significantly lower than those in NEVR from the third day to the 12th week after the treatment. The levels of core antigen less than 1000fmol/L in the second week could predict a better prognosis in the 12th week. The measurement of serum HCV core antigen was useful for the early prognosis of the treatment in CH-C patients with genotype 1b and high viral loads with Pegylated Interferon-α2b plus Ribavirin.
社団法人　日本肝臓学会の論文
2006-07-25